Considering the successful target engagement for both interventions in the DIAN-TU-001 trial, we investigated the effect of each drug on markers of AD-related pathology, in the context of their distinct mechanisms of action on respective forms of amyloid, and stage of disease by exploring longitudinal effects of gantenerumab and solanezumab on CSF and plasma levels of neurogranin, sTREM2, YKL-40, GFAP, and NfL. Here, NRGN is linked to Alzheimer disease.